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INTRODUCTION
Pregabalin is a frequently prescribed medication for 
neuropathic pain and generalized anxiety disorder1 with 
occasional use as antiepileptic medication1. 
Throughout the dorsal spinal cord and brain, 
gabapentin and pregabalin binding sites are present. 
It is Gamma-aminobutyric acid (GABA) analogue which 
acts as an inhibitory neurotransmitter. Pregabalin 
decreases excitatory neurotransmitter release in 
central nervous system which is responsible for pain 
pathways and epileptogenesis. Reportedly, α2δ subunit 
of presynaptic P/Q-type Calcium channels facilitates its 
action by ultimately decreased 
α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
receptor (AMPA) activation on noradrenergic nerve 
endings 1, 2, 3. Moreover, concentration of many 
neurotransmitters including substance P, glutamate, 
serotonin, dopamine, and noradrenaline are also 
decreased 4.
Reported elimination half-life of pregabalin is 5.5 to 6.7 
hours. It is exclusively excreted through kidneys with 
little hepatic metabolism. Daily effective dose is 
300-600mg, but lower doses are also effective in many 
cases. Dizziness and somnolence are the most 
frequent which are usually mild and short lasting1. 
Other common side effects are double vision, increase 
in bodyweight and balancing problems while reduced 
neutrophil count and hypersensitivity are uncommon 
ranging from 1 out of 100 to 1 in 1000 patients 5. 
Pregabalin is a precursor of gabapentin with similar 
effectiveness in diabetic peripheral neuropathy 
secondary to diabetes, post herpetic neuralgia and 
focal epilepsy 6,7,8. Side effect profile of pregabalin is 
more favourable than gabapentin justifying its 
increased used nowadays. Unfortunately, few case 
reports are published on drug reaction to pregabalin. 
A case report of  urticarial rash due to pregabalin and 
fall in neutrophils count  in a kidney transplant recipient 
was published in 2019 in BMC nephrology journal 9. 
Pregabalin-induced rash was rarely reported in Phase 3 
clinical trials, and there are few available reports on the
development of a rash due to pregabalin. In our case 
report, pregabalin was discontinued as soon as the 
patient complaint of rashes , within 1 week of starting 
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the drug .There was less possibility of any significant 
withdrawal effects. It is recommended to tapper the 
doses over 1 week duration if the patients are on 
pregabalin for long time. Still few health care 
professionals keep its side effects in mind while 
prescribing it to the patients and inform patient 
properly. Our aim of writing this case report is that the 
patient should be counselled about the side effect 
which can lead to morbidity and sometimes even 
mortality due to anaphylactic reaction if not diagnosed 
and managed on time. Pathogenesis of rashes caused 
by pregabalin is not clearly understood. 
Recommended practice is to start low doses of 
pregabalin and escalate gradually which may reduce 
the incidence of side effects10. Informed written 
consent of patient was taken before writing the case 
report.
CASE
A 30-year-old female patient, house maid, mother of 
3 children, presented to the neurology clinic with 
complaint of lower backache radiating to lower limbs 
with occasional numbness of her feet. There was no 
history of trauma or weightlifting. Bowel and bladder 
were unaffected. On the examination, There was no 
sensory level .Pin prick sensation were reduced in 
lumber L4,L5, sacral S1 dermatome bilaterally. 
Temperature, vibration, and proprioception sensation 
were intact. No motor weakness was found in proximal 
and distal muscles. Straight leg raising test was 
restricted to 60 degrees. Bilateral knee jerks were 
normal, but ankle reflexes were diminished bilaterally. 
She had no significant past medical or surgical history. 
No history of known allergy to any medication or food. 
No history of fever, body rashes, joint pains, or edema. 
Her backache on pain analogue scale was 7/10. She 
did not receive any medication for her back pain 
except for combination of acetaminophen and 
orphenadrine with the partial relief in her symptoms 
.She was prescribed pregabalin 75 mg at night along 
with acetaminophen and orphenadrine on as per need 
basis. Back care and physiotherapy for lumbosacral 
radiculopathy was advised with follow up after 2 
weeks. After 4 days, patient again visited our 
neurology clinic with complaints of itching and rashes 
all over body more marked on trunk and lower limbs 
(FIGURE 1-3 ) while hives were present on her 
forehead ,scalp, and face .(FIGURE4  ) No mucosal 
lesions were present. Her both hands were 
edematous (FIGURE 5-6 ), and she had pain and 
tenderness over elbow, knees, and ankles bilaterally 
without joint swelling, warmth, or redness.
She said to have these complaints after having 3rd 
dose of pregabalin and she thus stopped it. Pregabalin 
was stopped immediately. She was prescribed 
antihistamine injection pheniramine maleate (Avil  25 
mg ) and injection Decadron 4 mg stat , followed by 
tablet cetirizine (Zyrtec  10 mg ) 3 times daily. She 
was also advised blood work up to rule out any 
underlying causes including CBC. Hemoglobin 10.6 
g/dl normocytic, normochromic, platelet 441 per 
cmm,TLC 9.3 per cmm, ESR 42 mm/1st hr ,CRP 
normal.ANAprofile was negative URIC ACID 4.0 mg %, 
anti CCP negative (<0.5 U/ml) .After 1 week she was 
followed again in the clinic and showed complete 
resolution of all rashes, edema, and joint pains.
FIGURE 1: ERYTHEMATOUS RASHES ON THE 
LEFT THIGH OF PATIENT
FIGURE 4: ERYTHEMA AND REDNESS OF 
HANDS LEFT THIGH OF PATIENT
FIGURE 2: RASHES 
ON ARM 
FIGURE 3 : HIVES AND 
RASHES ON FOREHEAD
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DISCUSSION
Our case report emphasizes the significance of careful 
monitoring of drug side effects profile before 
prescribing it to patients along with regular follow up. 
Pregabalin is being frequently used for treating 
neuropathic pain. Numerous factors are proposed 
regarding increased chances of an individual to develop 
a drug-induced rash. These include woman of 
child-bearing age as in our case, the starting dose , 
co-existing viral illness, autoimmune disorders, 
pharmacological changes , and age of patient.11,12
To determine whether an adverse drug reaction was 
due to the drug instead of other factors, we decided to 
use The Naranjo Adverse Drug Reaction Probability 
Scale which has been used in literature13.10 
parameters are presented as questions including the 
relationship between drug administration and 
occurrence of event, any other causes for the event, 
drug levels, dose – response relationships and patient’s 
previous response of the medication. The drug-drug 
interactions are not included in this scale. The points 
are cut if another factor may be responsible for the 
adverse event while evaluating drugs individually for 
causality, thus weakening the causal association. Score 
are termed as definite, probable, possible or 
doubtful14.In our case it turned out to be a ‘‘probable’’ 
reaction (Score: 7).
 
The most frequently encountered drug-induced rash is 
erythematous resulting from delayed cell-mediated 
hypersensitivity. First or second week of therapy is the 
usual time duration13. There was a significant reduction 
of the mentioned lesions which were seen in our 
patient after the drug was stopped along with timely 
administration of symptomatic medications. 2 days 
after starting pregabalin, rashes appeared in the case 
reported by Smith et al15. Three large randomized 
controlled trials checked the risk and effectiveness of 
pregabalin in neuropathic patients. Pregabalin was 
found to be well tolerated in a six-week study on 246 
patients receiving 150 mg, 600 mg, or placebo.16. 
Light-headedness and sleepiness were the most 
common adverse effects. Similar adverse effects were 
reported by two other large clinical trials.17,18. A 
randomized, double-blind, placebo-controlled trial also 
showed good tolerance of pregabalin (600 mg/day) 
with peripheral oedema, light-headedness, increase in 
bodyweight and sleepiness as common adverse 
effects.19. 
In our patient in addition to erythematous and urticarial 
rashes, peripheral oedema and multiple joint pains 
were also present. The cause of peripheral oedema due 
to the gabapentinoids is not known, but it is 
common.7.6 % patients develop peripheral oedema as 
compared to 0.4% of patients on placebo therapy. 
Other literature reported Joint swelling in (1.9%) 
patients. This adverse effect resulted in 0.5% of 
pregabalin-related discontinuations in clinical trials 
compared with 0.2% of patients receiving placebo. 
There is no association between peripheral oedema 
and cardiovascular complications (hypertension or 
congestive heart failure), or with deteriorating kidney or 
liver function20. Our patient also developed oedema of 
hands as seen in the pictures without any symptoms or 
signs of cardiovascular or hepatic dysfunction.
5.2 % of older patients develop rashes as compared to 
usual range of 0.3% to 1.3%22.The  troublesome form 
of rash is a severe purpuric, vesiculobullar rash that 
may evolve into Stevens–Johnson syndrome. Joint pain 
occurs as a side effect in 6% of people. 
CONCLUSION
Although Pregabalin is thought to be an effective 
medication with frequently tolerable adverse effects, 
vigilant monitoring of patients is needed. It is being 
increasingly prescribed recently by neurologists, 
psychiatrists, and general practitioners. All health care 
professionals  should keep in mind the reported side 
effects and counsel patient about the possible side 
effects. Further research is needed regarding its 
pathogenesis of hypersensitivity, pharmacology, and 
safety parameters of pregabalin.
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